Voya Investment Management LLC Has $127,000 Stock Holdings in Immunome, Inc. $IMNM

Voya Investment Management LLC lifted its stake in Immunome, Inc. (NASDAQ:IMNM) by 21.2% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 18,905 shares of the company’s stock after acquiring an additional 3,305 shares during the period. Voya Investment Management LLC’s holdings in Immunome were worth $127,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also modified their holdings of the stock. Invesco Ltd. grew its stake in shares of Immunome by 6.4% in the first quarter. Invesco Ltd. now owns 28,379 shares of the company’s stock worth $191,000 after acquiring an additional 1,718 shares during the last quarter. Wealth Enhancement Advisory Services LLC boosted its stake in Immunome by 5.1% during the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 41,505 shares of the company’s stock worth $441,000 after buying an additional 2,005 shares in the last quarter. Wellington Management Group LLP raised its stake in shares of Immunome by 3.5% in the 4th quarter. Wellington Management Group LLP now owns 145,564 shares of the company’s stock valued at $1,546,000 after buying an additional 4,874 shares in the last quarter. Teacher Retirement System of Texas raised its stake in shares of Immunome by 49.0% in the 1st quarter. Teacher Retirement System of Texas now owns 17,360 shares of the company’s stock valued at $117,000 after buying an additional 5,712 shares in the last quarter. Finally, GAMMA Investing LLC raised its stake in shares of Immunome by 2,822.9% in the 1st quarter. GAMMA Investing LLC now owns 6,138 shares of the company’s stock valued at $410,000 after buying an additional 5,928 shares in the last quarter. Institutional investors and hedge funds own 44.58% of the company’s stock.

Wall Street Analyst Weigh In

IMNM has been the subject of a number of analyst reports. Evercore ISI initiated coverage on Immunome in a report on Friday, August 22nd. They set an “outperform” rating and a $18.00 price objective for the company. Guggenheim reissued a “buy” rating and set a $25.00 price objective on shares of Immunome in a report on Monday, August 25th. Craig Hallum initiated coverage on Immunome in a report on Friday, September 5th. They set a “buy” rating and a $26.00 price objective for the company. JPMorgan Chase & Co. cut their price objective on Immunome from $23.00 to $22.00 and set an “overweight” rating for the company in a report on Thursday, August 7th. Finally, The Goldman Sachs Group initiated coverage on Immunome in a report on Monday, September 22nd. They issued a “buy” rating and a $26.00 price target for the company. Ten investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $23.20.

Immunome Trading Up 3.3%

Immunome stock opened at $11.71 on Wednesday. The firm has a market capitalization of $1.02 billion, a P/E ratio of -3.80 and a beta of 1.92. Immunome, Inc. has a 1 year low of $5.15 and a 1 year high of $15.13. The business has a 50-day moving average of $10.14 and a 200-day moving average of $8.93.

Immunome (NASDAQ:IMNM) last issued its quarterly earnings data on Wednesday, August 6th. The company reported ($0.50) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.52) by $0.02. Immunome had a negative return on equity of 76.10% and a negative net margin of 1,687.08%.The business had revenue of $4.02 million during the quarter, compared to analyst estimates of $1.03 million. Research analysts anticipate that Immunome, Inc. will post -2.21 EPS for the current fiscal year.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.